AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04267887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03065569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 16 mL of 0.125% bupivacaine
Study NCT03065569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 16 mL of 0.125% bupivacaine
Study NCT04267887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02682459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 1
Description: Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 2
Description: Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 3
Description: Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 4
Description: Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 1- Cohort 5
Description: Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 2- Cohort 1
Description: Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 2- Cohort 2
Description: Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 2- Cohort 3
Description: Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
Study NCT04256174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 or placebo- Part 2- Cohort 4
Description: Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
Study NCT04452123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic argon plasma treatment of endometrioma
Description: Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
Study NCT04452123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary
Description: Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
Study NCT01889108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPEEDI
Description: Behavior intervention combining parent education and physical therapy intervention for preterm infants
Study NCT02837471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiezoRx medical grade pedometer
Description: Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program
Study NCT03047967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung function tests
Description: baby-body plethysmography
Study NCT00840177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 1.5 g/m2/day given by continuous IV on days 4-7
Study NCT03047967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal brushing
Description: Epithelial sample collecting for in vitro study
Study NCT02733822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Study NCT02733822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Study NCT00355355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talaporfin sodium
Description: LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
Study NCT00355355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interstitial Light Emitting Diodes
Description: 200 J/cm per Light Source at 20 mW/cm light energy
Study NCT00355355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous placement of device in the liver
Description: Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
Study NCT00355355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
Study NCT02267291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation
Description: Ventilatory support to alter intrathoracic pressure
Study NCT02840253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Study NCT01589146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: 4 weeks heparin prophylaxis
Study NCT03783962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Intervention - Cooking
Description: Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings.
Study NCT03783962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Demonstrations - Cooking
Description: The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
Study NCT03458325 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Furoscix Infusor
Description: Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
Study NCT00840177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: 12 mg/m2/day given intravenously over 10-15 minutes on days 4-6
Study NCT00840177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Description: 1,280 mg/day given orally on days 1-8
Study NCT01159275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Generic LPV/r and Aluvia (pharmacokinetics)
Description: Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
Study NCT01159275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aluvia and Generic LPV/r (pharmacokinetics)
Description: First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
Study NCT02612233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin or Duloxetine or Placebo
Description: This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
Study NCT02378961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food
Study NCT02612233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin or Duloxetine or Placebo
Description: This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
Study NCT03261908 — intervention group
Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study NCT04078126 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BFF
Description: Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
Study NCT04078126 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
Study NCT01727466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facing Your Fears
Description: FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
Study NCT01020136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
Study NCT04227236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-based virtual facilitator training for Making Proud Choices
Description: Participants complete the Making Proud Choices (MPC) facilitator training using an e-based virtual trainer on a computer. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
Study NCT04227236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person facilitator training for Making Proud Choices
Description: Participants complete the Making Proud Choices (MPC) facilitator training using the standard in-person training method. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
Study NCT03422367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
Study NCT03422367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
Study NCT00527865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
Study NCT00527865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing 10.5 mg of lactose will be supplied as placebo.
Study NCT03517696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Membrane sweeping
Description: Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
Study NCT02807168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NT-proBNP (Cardiac Biomarkers)
Study NCT02447796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
Study NCT02447796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
Study NCT03355014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of gemigliptin/metformin HCl sustained release 50/1000mg
Description: Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
Study NCT03355014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
Description: Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
Study NCT01423695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel plus trastuzumab
Description: Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
Study NCT04614012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treated with hyperimmune plasma
Description: administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
Study NCT01142076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xinju Xiaogao Prescription
Description: treatment group
Study NCT01142076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Therapeutic dose of 10%
Study NCT02327585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A randomized controlled study of Executive Function training for children with ADHD
Description: Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
Study NCT04058899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: sedative and might be analgesic drug
Study NCT04058899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: agonist antagonist narcotic
Study NCT04058899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infusion pump
Description: infusion pump for titration of fluid containing drug infusion
Study NCT00883948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal (Trophic) Feeding
Description: Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
Study NCT00883948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Feeding
Description: Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
Study NCT04393038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: ABX464 50mg QD for 28 days + Standard of Care
Study NCT04393038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50mg QD for 28 days + Standard of Care
Study NCT01389674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D-strain echo
Description: 2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis.
Study NCT02432781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink
Study NCT02432781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10% dextrose solution mixed with insulin 16 unit 100 mL/h
Study NCT03346083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Factor Xa inhibitor.
Study NCT04399200 — intervention group
Intervention type: DEVICE
Intervention: Treatment according to standard care recommandation
Description: SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
Study NCT03021603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hope Intervention
Description: The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets.
Study NCT03723798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 Low dose
Description: 3 tablets b.i.d for 12 weeks
Study NCT03723798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 Mid dose
Description: 3 tablets b.i.d for 12 weeks
Study NCT03723798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 High dose
Description: 3 tablets b.i.d for 12 weeks
Study NCT02014831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Study NCT03723798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets b.i.d for 12 weeks
Study NCT03351868 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene-modified autologous stem cells
Description: Infusion for 5x10\^6\~1x10\^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
Study NCT02351492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy and intraoperative cholangiography
Description: Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
Study NCT02351492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnet resonance cholangio-pancreaticography
Description: Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
Study NCT02351492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnet resonance imaging
Description: Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
Study NCT02351492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter
Description: Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
Study NCT02535013 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound with appropriate interventions depending on the ultrasound finding
Study NCT02535013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound with appropriate interventions depending on the ultrasound finding